Nucleoside diphosphate-linked moiety X-type motif 15 R139C genotypes impact 6-thioguanine nucleotide cut-off levels to predict thiopurine-induced leukopenia in Crohn's disease patients.
Adolescent
Adult
Aged
Asian People
/ genetics
Biological Variation, Population
/ genetics
Biomarkers
/ blood
Child
Crohn Disease
/ blood
Female
Guanine Nucleotides
/ blood
Humans
Immunosuppressive Agents
/ adverse effects
Leukopenia
/ chemically induced
Male
Mercaptopurine
/ adverse effects
Middle Aged
Polymorphism, Single Nucleotide
Predictive Value of Tests
Prognosis
Pyrophosphatases
/ genetics
Reference Values
Retrospective Studies
Thionucleotides
/ blood
Young Adult
Crohn’s disease
Nucleoside diphosphate-linked moiety X-type motif 15
Thioguanine nucleotide levels
Thiopurine-induced leukopenia
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
14 Oct 2019
14 Oct 2019
Historique:
received:
24
07
2019
revised:
05
09
2019
accepted:
11
09
2019
entrez:
23
10
2019
pubmed:
23
10
2019
medline:
27
2
2020
Statut:
ppublish
Résumé
Thiopurine-induced leukopenia (TIL) is a life-threatening toxicity and occurs with a high frequency in the Asian population. Although nucleoside diphosphate-linked moiety X-type motif 15 ( To determine the 6TGN cut-off levels after dividing patients into subgroups according to their Patients' clinical and epidemiological characteristics were collected from medical records from July 2014 to February 2017. A total of 411 Crohn's disease patients were included. TIL was observed in 72 individuals with a median 6TGN level of 323.4 pmol/8 × 10 The predictive sensitivity of TIL based on 6TGN is dramatically increased after subgrouping according to
Sections du résumé
BACKGROUND
BACKGROUND
Thiopurine-induced leukopenia (TIL) is a life-threatening toxicity and occurs with a high frequency in the Asian population. Although nucleoside diphosphate-linked moiety X-type motif 15 (
AIM
OBJECTIVE
To determine the 6TGN cut-off levels after dividing patients into subgroups according to their
METHODS
METHODS
Patients' clinical and epidemiological characteristics were collected from medical records from July 2014 to February 2017.
RESULTS
RESULTS
A total of 411 Crohn's disease patients were included. TIL was observed in 72 individuals with a median 6TGN level of 323.4 pmol/8 × 10
CONCLUSION
CONCLUSIONS
The predictive sensitivity of TIL based on 6TGN is dramatically increased after subgrouping according to
Identifiants
pubmed: 31636477
doi: 10.3748/wjg.v25.i38.5850
pmc: PMC6801191
doi:
Substances chimiques
Biomarkers
0
Guanine Nucleotides
0
Immunosuppressive Agents
0
Thionucleotides
0
6-thioguanylic acid
15867-02-4
Mercaptopurine
E7WED276I5
NUDT15 protein, human
EC 2.6.1.-
Pyrophosphatases
EC 3.6.1.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5850-5861Informations de copyright
©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: The authors declare no competing financial interests related to this study.
Références
J Gastroenterol Hepatol. 2019 Apr;34(4):679-685
pubmed: 30175864
J Gastroenterol. 2016 Jan;51(1):22-9
pubmed: 26590936
Gastroenterology. 2006 Apr;130(4):1047-53
pubmed: 16618398
Inflamm Bowel Dis. 2017 Jun;23(6):946-955
pubmed: 28452864
Dig Dis Sci. 2004 Jan;49(1):133-7
pubmed: 14992447
Gut. 2006 Oct;55(10):1423-31
pubmed: 16543290
Aliment Pharmacol Ther. 2019 Sep;50(5):484-506
pubmed: 31342537
Aliment Pharmacol Ther. 2016 Nov;44(9):967-975
pubmed: 27604507
Therap Adv Gastroenterol. 2016 Jul;9(4):449-56
pubmed: 27366213
J Crohns Colitis. 2017 Jan;11(1):3-25
pubmed: 27660341
Lancet Oncol. 2017 Apr;18(4):515-524
pubmed: 28258828
Aliment Pharmacol Ther. 2007 Apr 15;25(8):941-7
pubmed: 17402998
Inflamm Bowel Dis. 2010 Aug;16(8):1376-81
pubmed: 20049951
Clin Pharmacol Ther. 2019 May;105(5):1095-1105
pubmed: 30447069
Inflamm Bowel Dis. 2017 Sep;23(9):1592-1599
pubmed: 28570428
J Pediatr Gastroenterol Nutr. 2001 Oct;33(4):450-4
pubmed: 11698762
J Crohns Colitis. 2018 Apr 27;12(5):610-620
pubmed: 29293971
J Crohns Colitis. 2017 Jul 1;11(7):769-784
pubmed: 28513805
Front Pharmacol. 2018 Oct 08;9:1107
pubmed: 30349479
Nat Genet. 2014 Sep;46(9):1017-20
pubmed: 25108385
J Clin Oncol. 2015 Apr 10;33(11):1235-42
pubmed: 25624441
Cancer Res Treat. 2018 Jul;50(3):872-882
pubmed: 28903549
Intest Res. 2015 Jul;13(3):193-207
pubmed: 26130993
Aliment Pharmacol Ther. 2011 Nov;34(9):1106-14
pubmed: 21929546
J Crohns Colitis. 2017 Feb;11(2):175-184
pubmed: 27402913
Inflamm Bowel Dis. 2013 Jun;19(7):1404-10
pubmed: 23665964
Aliment Pharmacol Ther. 2016 Apr;43(8):863-883
pubmed: 26876431
Gastroenterology. 2000 Apr;118(4):705-13
pubmed: 10734022
Inflamm Bowel Dis. 2010 Sep;16(9):1541-9
pubmed: 20155846
Inflamm Bowel Dis. 2012 Jan;18(1):63-73
pubmed: 21381155
J Crohns Colitis. 2008 Dec;2(4):315-21
pubmed: 21172230
Pharmacogenet Genomics. 2017 Jun;27(6):236-239
pubmed: 28445187
Nat Genet. 2016 Apr;48(4):367-73
pubmed: 26878724
PLoS One. 2015 Sep 11;10(9):e0137798
pubmed: 26360046
Clin Chem. 1998 Mar;44(3):551-5
pubmed: 9510860
Cancer Res. 2016 Sep 15;76(18):5501-11
pubmed: 27530327
J Gastroenterol. 2018 Sep;53(9):1065-1078
pubmed: 29923122